Association Between Pharmaceutical Support and Basic Science Research on Erythropoiesis-Stimulating Agents

Author Affiliations: The South Carolina College of Pharmacy, the South Carolina Center of Economic Excellence for Medication Safety and Efficacy, and the Southern Network on Adverse Reactions (SONAR), Columbia (Dr Bennett); Department of Head and Neck Surgery, University of Texas M. D. Anderson Cancer Center, Houston, Texas (Dr Lai); Clinic for Radiation Oncology, University Hospital, Freiburg, Germany (Dr Henke); Center for Management of Complex Chronic Care and Department of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois (Dr Barnato); Department of Medicine, University of Nebraska School of Medicine, Omaha (Dr Armitage); and Departments of Medicine and Urology, Tulane University School of Medicine, New Orleans, Louisiana (Dr Sartor).

ConclusionsResearchers who do not have pharmaceutical industry support are more likely than those with pharmaceutical support to identify detrimental in vitro effects of ESAs. The potential for conflicts of interest to affect basic science research should be considered.